tarenflurbil has been researched along with Multiple Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alig, E; Dressman, J; Fink, L; Jung, F; Krollik, K; Li, D; Schmidt, MU; Thurn, M; Wacker, MG | 1 |
| Ashtikar, M; Geisslinger, G; Jung, F; Nothnagel, L; Parnham, MJ; Rossmanith, T; Thurn, M; Wacker, MG | 1 |
2 other study(ies) available for tarenflurbil and Multiple Sclerosis
| Article | Year |
|---|---|
Sustained-release hot melt extrudates of the weak acid TMP-001: A case study using PBB modelling.
Topics: Administration, Oral; Arginine; Biological Availability; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Drug Stability; Excipients; Flurbiprofen; Humans; Models, Biological; Multiple Sclerosis; Polymethacrylic Acids; Solubility; X-Ray Diffraction | 2021 |
Predictive PBPK modeling as a tool in the formulation of the drug candidate TMP-001.
Topics: Administration, Oral; Anti-Inflammatory Agents; Computer Simulation; Deglutition; Deglutition Disorders; Drug Compounding; Drug Liberation; Flurbiprofen; Gastric Emptying; Humans; Intestinal Absorption; Intestinal Mucosa; Models, Biological; Multiple Sclerosis; Solubility; Suspensions | 2019 |